Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including other brain neurons; strongest in gastric progenitor cells | 0.75 |
| chemistry Open Targets | hard to drug | 0.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | in no curated pathway | 0.00 |
No case: the score is under the bar. Receipt 16346
Sealed predictions
- FEZF1 in dopamine neurons, braak-0.24 (p 0.533) → -0.03 (p 0.944)receipt 16353
Swarm cases
receipt 16353: FEZF1 in dopamine neurons, braak
- power
- full sample -0.29 (p 0.246, n 18), 95% CI -0.67 to +0.21. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.28 (p 0.261, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.33 (p 0.182, n 18). could be the mix.
- skeptic
- leave-one-out range -0.42 to -0.20, sign flips 0; without severely affected donors -0.29 (p 0.246, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for FEZF1 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts